## AMENDMENTS TO THE CLAIMS

**1. (Withdrawn)** A pharmaceutical composition, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain with a pharmaceutically acceptable additive.

**2-3. (Cancelled)**

**4. (Withdrawn)** The composition according to claim 1, wherein the human recombinant HGF in which five amino acid residues are deleted in the first Kringle domain is any one of the following;

(a) a protein comprising an amino acid sequence described in SEQ ID NO: 1 of Sequence Listing; or

(b) a protein comprising an amino acid sequence in which one to several amino acid(s) is/are deleted, substituted or added in SEQ ID NO: 1 of Sequence Listing, and having the HGF activity.

**5. (Withdrawn)** A pharmaceutical composition, comprising a gene encoding a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain with a pharmaceutically acceptable additive.

**6-7. (Cancelled)**

**8. (Withdrawn)** The composition according to claim 5, wherein the gene encoding a human recombinant HGF in which five amino acid residues are deleted in the first Kringle domain is a gene comprising any one of the following DNAs;

(a) a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence listing;

(b) a DNA comprising a nucleotide sequence in which one to several nucleotide(s) is/are deleted, substituted or added in SEQ ID NO: 2 of Sequence Listing, and encoding a protein having the HGF activity;

(c) a DNA comprising a nucleotide sequence which hybridizes with a DNA comprising a nucleotide sequence complementary to a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing under the stringent condition, and encodes a protein having the HGF activity; or

(d) a DNA comprising a nucleotide sequence which has at least 70% or more homology with a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing, and encoding a protein having the HGF activity.

**9. (Withdrawn)** A method for treating a skin ulcer, comprising administering to a mammal a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain.

**10. (Withdrawn)** A method for promoting neovascularization, comprising administering to a mammal a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain.

**11-12. (Cancelled)**

**13. (Withdrawn)** A method for treating a skin ulcer, comprising administering to a mammal a gene encoding a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain.

**14. (Withdrawn)** A method for promoting neovascularization, comprising administering to a mammal a gene encoding a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain.

**15. (Withdrawn)** A method for promoting granulation formation, comprising administering to a mammal a gene encoding a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain.

**16. (Withdrawn)** The method according to any one of claims 13 to 15, wherein the gene encoding a human recombinant HGF in which five amino acid residues are deleted in the first Kringle domain is a gene comprising the following DNAs;

(a) a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing;

(b) a DNA comprising a nucleotide sequence in which one to several nucleotide(s) is/are deleted, substituted or added in SEQ ID NO: 2 of Sequence Listing, and encoding a protein having the HGF activity;

(c) a DNA comprising a nucleotide sequence which hybridizes with a DNA comprising a nucleotide sequence complementary to a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing under the stringent condition, and encodes a protein having the HGF activity; or

(d) a DNA comprising a nucleotide sequence which has at least 70% or more homology with a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing, and encodes a protein having the HGF activity.

**17. (Withdrawn)** A method for making a pharmaceutical composition, comprising mixing a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain, with a pharmaceutically acceptable additive.

**18-19. (Cancelled)**

**20. (Withdrawn)** The method according to claim 17, wherein the human recombinant HGF in which five amino acid residues are deleted in the first Kringle domain is any one of the following:

(a) a protein comprising an amino acid sequence described in SEQ ID NO: 1 of Sequence Listing; or

(b) a protein comprising an amino acid sequence in which one to several amino acid(s) is/are deleted, substituted or added in SEQ ID NO: 1 of Sequence Listing, and having the HGF activity.

**21. (Withdrawn)** A method of making a pharmaceutical composition, which comprises mixing a gene encoding a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain, with a pharmaceutically acceptable additive.

**22-23. (Cancelled)**

**24. (Withdrawn)** The method according to claim 21, wherein the gene encoding a human recombinant HGF in which five amino acid residues are deleted in the first Kringle domain is a gene comprising any one of the following DNAs;

(a) a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing;

(b) a DNA comprising a nucleotide sequence in which one to several nucleotide(s) is/are deleted, substituted or added in SEQ ID NO: 2 of Sequence Listing, and encoding a protein having the HGF activity;

(c) a DNA comprising a nucleotide sequence which hybridizes with a DNA comprising a nucleotide sequence complementary to a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing under the stringent condition, and encodes a protein having the HGF activity; or

(d) a DNA comprising a nucleotide sequence which has at least 70% or more homology with a DNA comprising a nucleotide sequence described in SEQ ID NO: 2 of Sequence Listing, and encodes a protein having the HGF activity.

**25. (Withdrawn)** A sealing-type wound covering material, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain in combination with a sealing-type wound covering material.

**26. (Withdrawn)** A kit for treating a skin ulcer, comprising a composition containing a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain, and a sealing-type wound covering material which can absorb an exudate from an affected part of skin ulcer.

**27. (Withdrawn)** A method for treating a skin ulcer, comprising covering wound surface with a sealing-type wound covering material which can absorb an exudate from the affected part of skin ulcer, maintaining the affected part of skin ulcer under the wet environment, and placing a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain, in a sealing-type wound covering material, or between a sealing-type wound covering material and wound surface.

**28. (New)** A method for promoting granulation formation and enhanced wound healing in a skin ulcer of a mammal comprising:

selecting a mammal having a skin ulcer to receive a drug that promotes granulation formation and enhanced wound healing in said skin ulcer; and

topically administering a drug that comprises a protein of the sequence of SEQ ID NO: 1 to said skin ulcer in an amount that promotes granulation formation and enhanced wound healing.

**29. (New)** The method of claim 28, further comprising analyzing the formation of granulation tissue at the skin ulcer of said mammal.

**30. (New)** The method of claim 28, wherein said drug further comprises a gelling agent.

**31. (New)** The method of claim 28, wherein said drug further comprises an antiseptic.

**32. (New)** The method of claim 28, wherein said drug further comprises a fatty acid ester.

**33. (New)** The method of claim 28, wherein said drug is in the form of a ointment.

**34. (New)** The method of claim 28, wherein said drug is in the form of a cream.

**35. (New)** The method of claim 28, wherein said drug is in the form of a gel.

**36. (New)** The method of claim 28, wherein said drug is in the form of a liquid.

**37. (New)** A method for promoting granulation formation and enhanced wound healing in a skin ulcer of a mammal comprising:

selecting a mammal having a skin ulcer to receive a drug that promotes granulation formation and enhanced wound healing in said skin ulcer;

topically administering a drug that comprises a protein of the sequence of SEQ ID NO: 1 to said skin ulcer in an amount that promotes granulation formation and enhanced wound healing; and

analyzing the formation of granulation tissue and wound healing at the skin ulcer of said mammal.

**38. (New)** The method of claim 37, wherein said drug further comprises a gelling agent.

**39. (New)** The method of claim 37, wherein said drug further comprises an antiseptic.

**40. (New)** The method of claim 37, wherein said drug further comprises a fatty acid ester.

**41. (New)** The method of claim 37, wherein said drug is in the form of a ointment.

**42. (New)** The method of claim 37, wherein said drug is in the form of a cream.

**43. (New)** The method of claim 37, wherein said drug is in the form of a gel.

**44. (New)** The method of claim 37, wherein said drug is in the form of a liquid.

**45. (New)** A method for promoting granulation formation and enhanced wound healing in a skin ulcer of a mammal comprising:

selecting a mammal having a skin ulcer to receive a drug that promotes granulation formation and enhanced wound healing in said skin ulcer;

providing a wound covering agent selected from the group consisting of a hydrocolloid dressing material, a hydrogen dressing material, a polyurethane dressing material, a hydropolymer dressing material, a hydrofiber dressing material, and a polyurethane foam;

contacting the skin ulcer of said mammal with said wound covering agent;

topically administering a drug that comprises a protein of the sequence of SEQ ID NO: 1 to said skin ulcer in an amount that promotes granulation formation and enhanced wound healing; and

analyzing the formation of granulation tissue and wound healing at the skin ulcer of said mammal.

**46. (New)** The method of claim 45, wherein said drug further comprises a gelling agent.

**47. (New)** The method of claim 45, wherein said drug further comprises an antiseptic.

**48. (New)** The method of claim 45, wherein said drug further comprises a fatty acid ester.

**49. (New)** The method of claim 45, wherein said drug is in the form of a ointment.

**50. (New)** The method of claim 45, wherein said drug is in the form of a cream.

**51. (New)** The method of claim 45, wherein said drug is in the form of a gel.

**52. (New)** The method of claim 45, wherein said drug is in the form of a liquid.